Pfizer posted first-quarter results that beat Wall Street expectations. The company reported adjusted diluted earnings of $1.62 per share for the period. Revenue for the first quarter was $25.7 billion. Covid-19 vaccine helped boost revenue for Pfizer, which has been in decline for several years. Pfizer’s first quarter results were better than the FactSet consensus estimate for first quarter of 2013-14. It’s not the first time Pfizer has posted quarterly results in the past two years that have topped expectations for the year-long period. For more information, visit Pfizer.com/www.pfizer.org/q1/2013-2014-14-13-13. For more details, visit . . .
[su_button url=’https://www.barrons.com/articles/pfizer-stock-earnings-paxlovid-vaccine-sales-51651583115′ target=’_blank’ style=’ghost’ background=’#010066′ color=’#010066′ size=’2′ wide=’no’ center=’no’ radius=’auto’]Read more at www.barrons.com[/su_button]
By
By
By
By
By
